Adriamycin (Doxorubicin) for Lymphoma | MyLymphomaTeam

Connect with others who understand.

sign up Log in
About MyLymphomaTeam
Powered By

Adriamycin, also known by its drug name doxorubicin, is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for treating Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple myeloma. Adriamycin is often combined with other drugs in specific chemotherapy regimens.

Adriamycin is an anticancer drug used in chemotherapy. Adriamycin is a member of a drug class called anthracycline antibiotics. Adriamycin is also a topoisomerase inhibitor. Adriamycin is believed to work by damaging DNA and blocking cell division in several ways.

How do I take it?
Adriamycin is usually administered as an intravenous infusion during chemotherapy treatment.

Side effects
The FDA-approved label for Adriamycin lists common side effects including hair loss, nausea, and vomiting.

Rare but serious side effects listed for Adriamycin include radiation-induced toxicity and fetal harm.

For more details about this treatment, visit:

Adriamycin PFS — RxList

Chemotherapy for Hodgkin Lymphoma — American Cancer Society

Chemotherapy for Non-Hodgkin Lymphoma — American Cancer Society

Drug Therapy for Multiple Myeloma — American Cancer Society

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in